Today (16 Aug. 2021)Chulalongkorn Hospital, Thai Red Cross and the Faculty of Medicine Chulalongkorn University gave a press release ChulaCOV19 vaccine test In the volunteers, accelerate the next phase of research.’
with Prof. Dr. Suthipong Watcharasin, Director of Chulalongkorn Hospital Thai Red Cross Society and Dean of the Faculty of Medicine Chulalongkorn University said that Chulalongkorn Hospital, the Thai Red Cross Society and the Research Center Faculty of Medicine, Chulalongkorn University has developed, researched, developed, invented and produced vaccines for use in preventing various diseases. to the public, including COVID-19 ChulaCov19 vaccine tested in the volunteers in phase 1 and continued in phase 2 under the supervision of many sectors including having a team of specialist doctors at the Vaccine Research Center Faculty of Medicine, Chulalongkorn University closely monitors To give people confidence in the highest safety of vaccination testing.
side Prof. Dr. Kiat Rakrungtham executive directorCOVID-19 Vaccine Development Project Vaccine Research Center Faculty of Medicine Chulalongkorn University said the development of this vaccine was supported by the National Vaccine Institute. National Research Office (NRCT) Second Century Scholarship Chulalongkorn University and donations from the Chulalongkorn University Medical Alumni Association Vaccine Research Donation Fund, Thai Red Cross Society
However ChulaCov19 vaccine is an mRNA vaccine. That has been tested in animals, both rats and monkeys were found to be effective. Build a high level of immunity Subsequently, a trial in 36 volunteers aged 18-55 years in June found no serious side effects. There were mild or moderate side effects such as fatigue, low-grade fever and some chills among the volunteers who received the 2nd dose. will improve within an average of 1-3 days
“The results of the experiment inChulaCov19 Vaccination Volunteer Group Found that can stimulate the immune system of antibodies. It is comparable to that of an mRNA vaccine like Pfizer. It inhibits protein binding at the spiny group 94%, as well as Pfizer 94%, as well as being able to activate very high antibodies against the original strain. This high antibody suppresses all four cross-species strains: Alpha, Beta, Gamma and Delta. It can also stimulate T-cell immunity, thereby eliminating and controlling the germs present in infected cells. Yes,” said Prof. Dr. Kiat.
ChulaCov19 vaccine is an invention designed and developed by Thai people in collaboration with Dr. Scientist who invented the technology, Prof. Drew Weissman, University of Pennsylvania. ChulaCov19 vaccine is made by creating tiny parts from the genetic material of the coronavirus. (Without the use of infection in any way), which when the body receives this tiny piece of genetic material. It builds into the spike protein and stimulates the immune response to fight the virus when it comes in contact with the virus. Within a few days, this mRNA is destroyed without any accumulation in the body.
However, such testing It was in phase 1 divided into two age groups of 72 people.
The first group consisted of 36 volunteers aged 18-55 years old.
The second group consisted of 36 volunteers aged 65-75 years old.
The two groups above were divided into subgroups vaccinated with 10 mcg, 25 mcg and 50 mcg to determine at what dose ChulaCov19 vaccine was most effective. Because Moderna currently uses 100 micrograms of the vaccine and Pfizer uses 30 micrograms, the center must study whether Thais or Asians are suitable for injections of 10 or 25 or 50 micrograms in order to know the safe dose and highly stimulate the immune system. After that, it goes into Phase 2 clinical testing.
Follow the news on Line
.
